Osteoarthritis (OA) is the most-studied indication for cannabidiol (CBD) in dogs, with several randomised, placebo-controlled trials now published. This is a concise review of the evidence, mechanism, dosing and safety, for practitioners considering CBD as part of a multimodal analgesia plan.
The clinical evidence (randomised trials)
| Study | Design | Dose | Key finding |
|---|---|---|---|
| Gamble et al. 2018 (Frontiers Vet Sci) | RCT crossover, n=16 | 2 mg/kg BID | Significant ↓ pain (CBPI) and ↑ activity; well tolerated |
| Verrico et al. 2020 (Pain) | RCT, n=20 | 20–50 mg/day (≈1.2 mg/kg) | Dose-dependent ↓ pain scores vs placebo |
| Brioschi et al. 2020 | RCT add-on to multimodal | 2 mg/kg BID | Improved analgesia as adjunct; reduced rescue needs |
| Mejia et al. 2021 | RCT, n=23 | 2.5 mg/kg BID | No significant difference vs placebo at this dose/duration |
The weight of evidence supports a clinically meaningful analgesic effect at ~2 mg/kg twice daily, most consistently as an adjunct to established therapy. Results are not universally positive (Mejia 2021), underscoring dose and duration dependence.
Mechanism (why it complements NSAIDs)
CBD reduces inflammation and nociception via pathways distinct from COX: PPARγ activation, NF-κB inhibition, adenosine signalling, and TRPV1 modulation. Because it does not rely on cyclo-oxygenase, it is mechanistically complementary to NSAIDs and to anti-NGF monoclonal antibodies (bedinvetmab/frunevetmab) rather than competitive — an additive multimodal option.
Practical dosing
- Starting dose: 1–2 mg/kg PO BID of a broad-spectrum product; titrate to response over 2–4 weeks.
- Cats: start lower (0.5 mg/kg) — slower hepatic clearance.
- Administration: with food improves absorption; timing is flexible for OA co-medications that are mostly independent (see the drug-interaction framework).
Safety & monitoring
The most consistent finding across safety studies (Vaughn 2021; Corsato Alvarenga 2023) is a dose-dependent, reversible rise in ALP — enzyme induction without demonstrated hepatic injury at therapeutic doses. Baseline hepatic panel is prudent, especially when combining with hepatically-cleared or hepatotoxic co-medications. GI signs (soft stool, inappetence) are the main tolerability issue at higher doses.
Integrating with other OA medications
Most OA co-drugs are pharmacologically independent of CBD (NSAIDs, gabapentin, bedinvetmab) — combine freely. Tramadol shares hepatic (CYP2B11) and receptor overlap and warrants dose spacing. For a full tier-by-tier interaction framework, see our companion reference on CBD & polypharmacy in dogs and cats.
Key references
Gamble LJ, et al. Pharmacokinetics, safety, and clinical efficacy of cannabidiol treatment in osteoarthritic dogs. Front Vet Sci. 2018. · Verrico CD, et al. A randomized, double-blind, placebo-controlled study of daily cannabidiol for canine osteoarthritis pain. Pain. 2020. · Brioschi FA, et al. Oral CBD as an add-on to multimodal analgesia in dogs with OA. 2020. · Mejia S, et al. Evaluation of oral CBD for OA pain in dogs. 2021. · Vaughn DM, et al. 28-day safety and PK of repeated oral CBD in healthy dogs. AJVR. 2021. · Corsato Alvarenga I, et al. Tolerability of long-term CBD supplementation in healthy adult dogs. JVIM. 2023.
Compiled from peer-reviewed research for licensed veterinary professionals. Not a substitute for individual clinical judgement or local cannabinoid regulations.